| Literature DB >> 30452654 |
José A Bengoechea1, Joana Sa Pessoa1.
Abstract
Klebsiella species cause a wide range of diseases including pneumonia, urinary tract infections (UTIs), bloodstream infections and sepsis. These infections are particularly a problem among neonates, elderly and immunocompromised individuals. Klebsiella is also responsible for a significant number of community-acquired infections. A defining feature of these infections is their morbidity and mortality, and the Klebsiella strains associated with them are considered hypervirulent. The increasing isolation of multidrug-resistant strains has significantly narrowed, or in some settings completely removed, the therapeutic options for the treatment of Klebsiella infections. Not surprisingly, this pathogen has then been singled out as an 'urgent threat to human health' by several organisations. This review summarises the tremendous progress that has been made to uncover the sophisticated immune evasion strategies of K. pneumoniae. The co-evolution of Klebsiella in response to the challenge of an activated immune has made Klebsiella a formidable pathogen exploiting stealth strategies and actively suppressing innate immune defences to overcome host responses to survive in the tissues. A better understanding of Klebsiella immune evasion strategies in the context of the host-pathogen interactions is pivotal to develop new therapeutics, which can be based on antagonising the anti-immune strategies of this pathogen. © FEMS 2018.Entities:
Keywords: zzm321990 Klebsiellazzm321990 ; innate immunity; virulence
Mesh:
Year: 2019 PMID: 30452654 PMCID: PMC6435446 DOI: 10.1093/femsre/fuy043
Source DB: PubMed Journal: FEMS Microbiol Rev ISSN: 0168-6445 Impact factor: 16.408
Models to assess K. pneumoniae infection biology.
| Infection model | Useful to assess | Advantages | Limitations |
|---|---|---|---|
|
| Recapitulates many clinical aspects of | Well-established model. Available knock-out and knock-in animals. | Costs. Differences between mice and human immune system. |
|
| Recapitulates interactions with phagocytic cells. | Easy to handle. Available genetic tools, and bank of mutant strains. | Growth conditions (temperature and growth medium to assess virulence). |
|
| Early interactions with ancient antibacterial mechanisms. | Easy to handle. Available genetic tools, and bank of mutant strains. | Growth conditions. Not clear how to translate findings in this model to model human disease. |
|
| Early interactions between a pathogen and a host. | Easy to handle. Available genetic tools, and bank of mutant strains. | Growth conditions. Not clear how to translate findings in this model to model human disease. |
|
| Recapitulates interactions with innate immune system (effectors and phagocytes). | Easy to handle. Growth conditions (temperature). Good correlation with the mouse model in terms of assessing virulence. | Lack of genetic tools, and bank of mutant strains. |
|
| Interactions with a complex immune system | Possibility of easily imaging infection. Available genetic tools, and bank of mutant strains. | Need for costly infrastructure. Not clear how to translate findings in this model to model human disease. |
Figure 1.Mechanisms of innate immunity to K. pneumoniae infections. The figure depicts the cells implicated in containing K. pneumoniae infection. There is conclusive evidence demonstrating the interaction of K. pneumoniae with neutrophils, macrophages (and monocytes [not shown]), dendritic cells and epithelial cells. These interactions are marked with black arrows. The interaction with different subset of T cells, NK cells and other lymphocytes has not been investigated yet, although these cells participate in bacterial clearance. The network of connections between cells, and the role played by different cytokines activating host responses are depicted with blue arrows.
Immune evasion strategies of K. pneumoniae.
| Immune evasion strategies | Mechanism | Bacterial factor | References |
|---|---|---|---|
| (i) Stealth pathogen | |||
| Preventing the antimicrobial action of soluble innate immune effectors | |||
| Preventing complement bactericidal effect, and opsonisation | Limiting C3b deposition | CPS, LPS O-polysaccharide | Merino |
| Limiting antimicrobial activity of collectins | Blunting interaction with SP-A and SP-D | CPS | Kabha |
| Counteracting bactericidal action CAMPs and polymyxins | Limiting the interaction with the bacterial surface. Efllux of CAMPs. | CPS, LPS lipid A decorations, AcrAB | Campos |
| Attenuating the interaction with immune cells | |||
| Attenuating engulfment by epithelial cells | CPS | Cortes | |
| Avoiding phagocytosis by neutrophils | CPS, OmpK36 | Regueiro | |
| Avoiding phagocytosis by macrophages | CPS, LPS lipid A decorations, OmpA, OmpK36 | March | |
| Limiting the activation of PPRs | Limiting the recognition of LPS by TLR4 | LPS lipid A 2-hydroxylation | Llobet |
| (ii) Subversion host defences | |||
| Attenuating cell-intrinsic immunity | |||
| Controlling maturation dendritic cells | CPS, LPS O-polysaccharide | Evrard | |
| Manipulation phagosome maturation | Activation PI3K-AKT-Rab14 axis | Unknown | Cano |
| Controlling cell death | Cytotoxicity in epithelial cells. Triggering apoptosis in macrophages. | CPS Unknown | Cano |
| Abrogating TLR-controlled inflammatory responses: | |||
| Abolishing TLR signalling | CPS, LPS O-polysaccharide, OmpA, T2SS | March | |
| Blunting NF-κB signalling | Upregulation deubiquitinase CYLD by targeting NOD1 and EGFR. | CPS, and other unknown factor(s) | Regueiro |
| Blunting MAPKs | Upregulation MAPKs phosphatase MKP-1 via NOD1 activation. | Unknown | Regueiro |
| Manipulating mucosal immunity | Induction of IL10. | Unknown | Greenberger |
| Counteracting nutritional immunity | Secretion of several siderophores | Yersiniabactin, salmochelin, aerobactin | Lawlor, O’connor and Miller |